Hematopoietic stem cell transplantation for adults with EBV-positive T- or NK-cell lymphoproliferative disorders: efficacy and predictive markers

[1] Jones JF(1988)T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections N Engl J Med 318 733-741

[2] Shurin S(2006)Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16 251-261

[3] Abramowsky C(2012)EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases Blood 119 673-686

[4] Tubbs RR(2011)Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection Bone Marrow Transplant 46 77-83

[5] Sciotto CG(2005)Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection Am J Hematol 80 64-69

[6] Wahl R(2013)Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 452-458

[7] Kimura H(2008)Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD Pathol Int 58 209-217

[8] Kimura H(2001)Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction Transplantation 72 1012-1019

[9] Ito Y(2011)High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts Bone Marrow Transplant 46 1104-1112

[10] Kawabe S(2012)Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy Int J Hematol 96 669-673

[1] Jones JF(1988)T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections N Engl J Med 318 733-741

[2] Shurin S(2006)Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16 251-261

[3] Abramowsky C(2012)EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases Blood 119 673-686

[4] Tubbs RR(2011)Excellent outcome of allogeneic hematopoietic SCT with reduced-intensity conditioning for the treatment of chronic active EBV infection Bone Marrow Transplant 46 77-83

[5] Sciotto CG(2005)Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection Am J Hematol 80 64-69

[6] Wahl R(2013)Investigation of the freely available easy-to-use software 'EZR' for medical statistics Bone Marrow Transplant 48 452-458

[7] Kimura H(2008)Proposed categorization of pathological states of EBV-associated T/natural killer-cell lymphoproliferative disorder (LPD) in children and young adults: overlap with chronic active EBV infection and infantile fulminant EBV T-LPD Pathol Int 58 209-217

[8] Kimura H(2001)Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction Transplantation 72 1012-1019

[9] Ito Y(2011)High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts Bone Marrow Transplant 46 1104-1112

[10] Kawabe S(2012)Sequential monitoring of serum IL-6, TNF-α, and IFN-γ levels in a CAEBV patient treated by plasma exchange and immunochemotherapy Int J Hematol 96 669-673